INTRODUCTION
There is increasing evidence that the process of carcinogenesis is causally related to the acquisition of a series of genetic lesions. Correction of these lesions can have therapeutic effects and reverse malignant transformation. This has produced much interest in the prospects for cancer gene therapy [1] [2] [3] . Although a few achievements have recently been made in the field of cancer gene therapy, great effort is still needed to select effective transgenes with multiple efficacy against cancers and to design specific gene vectors selectively targeting cancer cells. Approaches incorporating transgenes in conditionally replicative adenoviruses (CRAdTs) have attracted much attention [4, 5] . Genetic reengineering of CRAdTs by incorporating therapeutic payloads may yield mutually supportive antitumor effects. CRAd replication selectively amplifies therapeutic transgene expression in cancer cells [6, 7] , and transgene expression synchronously increases the spread of viral progeny within a tumor cell mass [8, 9] . It has been shown that gene-viral therapeutic approaches combining gene therapy with oncolytic virotherapy are more effective than the use of these methods individually.
Many attempts have been made to improve both the antitumor potency and safety by approaches combining viral oncolytic therapy and transgene therapy, and many therapeutic transgenes have exhibited efficacy in exper-imental models [10] [11] [12] . Among the numerous candidate genes and optional strategies, the direct transfer of immune regulatory genes, such as TNF-a, IL-4, IL-12, or IFN, to tumor cells by CRAdTs emerged as a powerful immunotherapeutic tool and inhibited tumor growth. IFN-g exerts mainly an immune regulatory effect but hardly results in the anti-virus effect compared with IFNa and IFN-h. It has been demonstrated that IFN-g can enhance antitumor immune response by upregulating major histocompatibility complex class I expression and accentuating the migration of specific and nonspecific immune cells to necrotic areas that develop spontaneously in large tumors [13] [14] [15] . Gene transfer of IFN-c inhibits tumor neovascularization by inducing apoptosis of endothelial cells in vivo [16, 17] , suggesting that IFN-g represses tumor growth by the dual mechanisms of inhibition of angiogenesis and elicitation of an immunotherapeutic response. Furthermore, administration of IFN-c with recombinant adenovirus into mice can decrease the activation of TH2 cells and formation of neutralizing antibody, allowing efficient repeat administration of virus [18] . Based on dual antitumor features of the IFN-c gene and tumor-selective replication of viruses, CRAdTs armed with the IFN-c gene could amplify transgene copies in tumor cells and produce high local concentrations of IFN-g in tumor tissues. This strategy of immune gene-viral therapy could thus yield multiple antitumor effects including oncolysis, antiangiogenesis, and induction of immune response.
In this study, we used the human (h) TERT promoterregulated CRAd CNHK300 [19] to construct novel immune gene-viral therapeutic systems termed CNHK300-mIFN-g and CNHK300-hIFN-g, which carry mouse (m) IFN-c or hIFN-c as the antitumor cytokine [20] . The systems exhibited triplex antitumor activity, including oncolysis, antiangiogenesis, and induction of immune response due to CRAd selective replication and transgene expression in cancer cells in vivo. Our study confirmed that this novel therapeutic strategy, termed immune gene-viral therapy, can overcome the disadvantages of traditional cancer gene therapy and display highly efficient antitumor activity even in tumor models with large tumors in athymic and immunocompetent mice.
RESULTS AND DISCUSSION
The Merits and Weaknesses of Immune Therapy by CRAd Indeed evidence from both preclinical and clinical studies suggested that the antitumor effects of CRAdTs would be enhanced by arming the immune regulatory genes [10] . For safety reasons, the accurate manipulation of CRAd replication exhibited high tumor selectivity, led to amplification and spread of the immune regulatory genes within cancer tissues, but spared normal tissues. But, ultimately, this approach will meet the major obstacle, the interplay of the virus with the immune system. Few data from preclinical studies on the interaction of the immune system with CRAdTs have been obtained because of the poor replication of human adenovirus in other species and the lack of appropriate immunocompetent animal models. In the early clinical trials, it seemed that the preexisting, low-level neutralizing antibody was not sufficient to limit the propagation of CRAdTs [21] . There was some evidence that the route of CRAd administration plays a critical role in determining the strength of the neutralization [5] . The neutralizing antibody did not appear to block CRAd efficacy when injected intratumorally, whereas the neutralizing antibody actually curtailed the CRAd efficacy when injected iv. Furthermore, it appeared that the repetitive CRAd injections would suppress the tumor regrowth and improve CRAd efficacy [10] . However, much in this field remains to do, and every step of the endeavor might be able to increase the oncolytic outcome of CRAdTs and abrogate the neutralization against adenoviral vectors.
Selective Replication of Adenoviruses
The hTERT promoter can be used to regulate the essential adenoviral genes to target many types of cancer [22] [23] [24] . We introduced a modified hTERT promoter into CNHK300 to control the adenoviral E1a gene [19] , then we inserted the mIFN-c expression cassette into the genome of CNHK300 upstream of the E1 region and generated the novel replicative adenovirus CNHK300-mIFN-g (Fig. 1) . We constructed
A schematic diagram of CNHK300-mIFN-g or CNHK300-hIFN-g. A modified hTERT promoter (hTERTp) was used to control the E1a gene. An expression cassette encoding the CMV promoter (CMVp), IFN-g cDNA, and SV40 poly(A) was inserted between the adenoviral package signal and the hTERT promoter. ITR, inverted terminal repeats; c, adenovirus 5 packaging signal. CNHK300-hIFN-g as well by switching mIFN-c to hIFN-c The in vitro results showed that these oncolytic adenoviruses selectively replicated in various cancer cells, and the yield of virus production per cell was about hundreds of times compared with that in normal cell lines ( Figs. 2A and 2B) . Compared with CNHK300, the replicative ability of CNHK300-mIFN-g or CNHK300-hIFN-g was decreased in most cancer cells, likely due to the production of IFN-g. Western blot analysis showed that E1a was expressed in tested cancer cells, but not in normal cells following infection of CNHK300-mIFN-g, CNHK300-hIFN-g, or CNHK300 (Figs. 2C and 2D ). In agreement with previous studies [25] , the E1a gene was weakly expressed in mouse hepatocyte carcinoma Hepa1-6 cells infected with CNHK300-mIFN-g or CNHK300, but not in those infected with Ad-mIFN-g (Fig. 2E) . The replicative activity of human adenovirus in mouse cancer cells enabled us to investigate the antitumor efficacy of CRAdTs expressing an immunostimulator in immunocompetent mice. The results proved that CNHK300, CNHK300-mIFN-g, and CNHK300-hIFN-g achieved the desired specificity for cancer cells by controlling the E1a expression with the hTERT promoter. Transgene Expression in Vitro and in Vivo IFN-g is vital to the promotion of tumor surveillance through various mechanisms [26, 27] . Even in immunodeficient animals, delivery of IFN-g can partially restore significant immune activity [28] . The effect of IFN-g is relatively species-specific. hIFN-g is active on human cells or primate cells, whereas mIFN-g may exert its effect on both human and mouse cells [29, 30] and result in the regression of both human and mouse tumors on immunodeficient and immunocompetent mice, though the effect of mIFN-g is slightly weaker on human cancer cells.
In this study, by Western blot, the expression level of mIFN-g (16 kDa) in supernatants of cancer cells infected with CNHK300-mIFN-g was higher than that in cells infected with Ad-mIFN-g (Fig. 3A) . By ELISA, CNHK300-mIFN-g expressed mIFN-g with high efficiency in cancer cells. The mean contents of mIFN-g in supernatants of cancer cell lines reached 11.58 F 3.34 to 175.59 F 17.38 ng/ml at 48 h, with an overall mean of 86.00 F 7.38 ng/ml, and reached 81.56 F 12.54 to 993.60 F 96.35 ng/ml at 72 h after infection, with an overall mean of 494.34 F 75.98 ng/ ml, which was about 142.77-and 567.59-fold of the levels in corresponding cells infected with Ad-mIFN-g, respectively (Fig. 3B) . In normal cells, however, the expression of mIFN-g by CNHK300-mIFN-g was similar to that by AdmIFN-g. In SMMC-7721 tumor models, expression of mIFN-g in mouse serum was 0.21 F 0.01 ng/ml at 3 days and 1.73 F 0.19 ng/ml at 7 days after treatment with CNHK300-mIFN-g, but 0.02 F 0.01 ng/ml at 3 days and not detectable at 7 days in the Ad-mIFN-g group. The results suggested that CNHK300-mIFN-g could efficiently express more mIFN-g than Ad-mIFN-g in cancer cells in vitro and in vivo. By using CRAdTs to carry transgenes, gene expression could be restricted to cancer cells, avoiding the systemic toxicity of IFN product as well as overcoming the low rate of transduction and poor antitumor gene expression of gene therapy in general.
Cell Viability
For assessing the selectivity and safety features of CNHK300-mIFN-g, CNHK300-hIFN-g, and CNHK300 in comparison with ONYX-015, we used the MTT assay to quantify cell viability. The oncolytic adenoviruses could selectively kill cancer cells at very low multiplicity of infection (m.o.i.) and spare normal cells even at higher m.o.i. (Fig. 4) . Cell viability was below 40% in cancer cells infected with oncolytic adenoviruses at a m.o.i. of 1 pfu/ cell, but more than 80% in normal cells infected with these viruses at a m.o.i. of 10 pfu/cell. The m.o.i. associated with 50% cell viability (IC 50 ) for CNHK300-mIFN-g ranged from 0.0054 to 1.1423 in cancer cells, but 356.5119 to 478.6170 in various normal cells. The IC 50 in normal cell lines was 866-fold that in tumor cell lines. Hep3B was particularly sensitive to CNHK300-mIFN-g, with viability below 40% at a m.o.i. of 0.01 pfu/cell. The oncolytic effect of CNHK300-mIFN-g was slightly weaker than that of CNHK300. ONYX-015 also had a killing effect on cancer cells, but required a higher m.o.i. to exhibit the same effect as CNHK300-mIFN-g and CNHK300. CNHK300-hIFN-g also had clear oncolytic effects on cancer cells at very low m.o.i. while sparing normal cells even at relative high m.o.i., demonstrating that there is no obvious negative effect of hIFN-g production on normal cells.
Antitumor Efficacy of CNHK300-mIFN-; in Mouse Models
We administered CNHK300-mIFN-g and CNHK300 intratumorally to determine their antitumor activity in vivo in established tumor models in immunodeficient and immunocompetent mice. In SMMC-7721 tumor models, 6 weeks after treatment, the group injected with viruses exhibited excellent therapeutic efficacy compared with the control group ( P = 0.0001 for CNHK300-mIFN-g, CNHK300, ONYX-015 groups, and P = 0.0009 for AdmIFN-g group) (Fig. 5A) . The efficacy of CNHK300-mIFNg, with a tumor inhibition rate of 75.9%, was better than those of CNHK300, ONYX-015, and Ad-mIFN-g, whose tumor inhibition rates were 48.3, 42.7, and 27.1%, respectively. In Hep3B models, 8 weeks later, the efficient antitumor activity was observed only in the CNHK300-mIFN-g group, which featured a tumor inhibition rate of 66.1% ( P = 0.0001). The groups treated with CNHK300, ONYX-015, and Ad-mIFN-g exhibited weak therapeutic effects ( P = 0.0667, 0.0794, and 0.2049 vs control group, respectively), with tumor inhibition rates below 18.0% (Fig. 5B) . In Hepa1-6 tumor models in immunocompetent mice, 4 weeks after the first injection, the efficient antitumor activity was observed in each virus-treated group, with tumor inhibition rates of 90.3, 61.9, 57.7, and 34.8% in the CNHK300-mIFN-g, CNHK300, Ad-mIFN-g, and ONYX-015 groups, respectively, compared with the control group ( P = 0.0001 for CNHK300-mIFN-g and CNHK300 groups, P = 0.0002 and 0.0006 for Ad-mIFN-g and ONYX-015, respectively) (Fig. 5C ). CNHK300-mIFN-g was markedly better than the summation of Ad-mIFN-g and CNHK300 on antitumor efficacies, suggesting that CNHK300-mIFN-g yielded synergistic antitumor effects in these tumor models ( P = 0.0001, 0.0003, 0.0496 in Hep3B, Hepa1-6, SMMC-7721 models, respectively).
These results demonstrated that multiple injections of CNHK300-mIFN-g, which combined virotherapy of the replicative adenovirus CNHK300 and immune gene therapy of the transgene mIFN-c, induced regression of small xenografts in SMMC-7721 models in nude mice and that the antitumor effect of CNHK300-mIFN-g was superior to those of CNHK300 and ONYX-015. The efficient antitumor activity of CNHK300-mIFN-g, as well as CNHK300 and ONYX-015, was due to selective viral replication in cancer cells and direct oncolysis. However, in Hep3B models with large xenografts, CNHK300 and ONYX-015 had little therapeutic effect, whereas CNHK300-mIFN-g still exhibited a remarkable therapeutic effect. It has been shown that virotherapy alone has limited ability to destroy large established tumors. In fact, ONYX-015 achieved less than 14% partial to complete regression when used alone in clinical trials on head and neck carcinoma [31] . CNHK300-mIFN-g continued to display efficient antitumor efficacy in large-volume tumor xenografts. Thus, the enhancement of antitumor efficacy of CNHK300-mIFN-g, compared with that of CNHK300, was due to expression of mIFN-c, which exerted a significant antitumor effect in immunodeficient animals.
To enhance antitumor efficacy, CRAdTs can be designed to function as therapeutic gene delivery vehicles by incorporating antitumor transgenes [25, 32] . Previous studies confirmed the antitumor activity of various vectors carrying cytokine genes, such as IFNs [33, 34] . CNHK300 also was armed with the mouse endostatin gene and induced tumor regression via antiangiogenesis [12] . When these therapeutic genes were inserted into the genome of CRAdTs, they were selectively and highly expressed in cancer cells as a result of selective viral replication, which further enhanced the therapeutic effect targeting cancer cells without toxicity to normal cells. The antitumor therapeutic effect of CNHK300-mIFN-g was stronger in vivo but weaker in vitro than that of CNHK300 (Figs. 4 and 5) . The reason for this discrepancy may be the stronger in vitro replication ability of CNHK300, but CNHK300-mIFN-g-induced mIFN-g production mediated powerful antitumor effects in vivo. The present in vivo study also found that more effective antitumor immune responses were exhibited when CNHK300-mIFN-g was used in immunocompetent hosts compared to immunodeficient animals, since in the former mIFN-g was fully functional because of the hostTs intact immune responses. In Hepa1-6 tumor models in BALB/c normal mice, CNHK300-mIFN-g completely inhibited the growth of tumors, and the antitumor efficacy of Ad-mIFN-g was clearly enhanced compared with SMMC-7721 and Hep3B models in BALB/c nude mice, suggesting that mIFN-g expression in immunocompetent mice mobilized a series of immune responses to inhibit the growth of cancer cells. CNHK300 yielded stronger antitumor effects than Ad-mIFN-g, with tumor inhibition rates of 48.3% vs 27.1% in SMMC-7721 models, 17.5% vs 5.1% in Hep3B models, and 61.9% vs 57.7% in Hepa1-6 models. By these preclinical models, it was demonstrated that the oncolytic effects of replicative adenoviruses provided most of the antitumor activity compared with the immune response to mIFN-g expression in the immunodeficient mice ( P = 0.0017 and 0.0474 in SMMC-7721 and Hep3B models, respectively), but the immune response was enhanced in immunocompetent mice and provided the antitumor activity as well as the oncolytic effect ( P = 0.4341).
Pathologic Examination
Pathologic examination of tumor specimens taken from tumor models revealed many necrotic foci in tumor tissues of every group in Hep3B models in immunodeficient mice. Necrotic area was greater than 78.6% in the CNHK300-mIFN-g group (Fig. 6A) and ranged from 38.2 to 56.4% in the other groups (Fig. 6B) . Many cancer cells of the CNHK300-mIFN-g group were positive for adenoviral capsid protein, and these cells were distributed mainly around the necrotic foci (Fig. 6C ), suggesting selective replication and an oncolytic effect of CNHK300-mIFN-g in cancer cells. The microvessel density (MVD) in tumor tissues was 14.0 F 6.1 in the CNHK300-mIFN-gtreated group compared with 52.0 F 3.0 in the control group ( P = 0.0006) (Figs. 6D and 6E ). MVDs in other groups were similar to that in the control group (Fig. 6F) . The number of microvessels was clearly decreased in tumor tissues of the CNHK300-mIFN-g group, which may be one of the mechanisms of mIFN-g-mediated antitumor responses in mice, since suppressing tumor angiogenesis could lead to tumor starvation and regression [27] . Additional mechanisms may account for the repression of tumor growth mediated by mIFN-g expression in immunocompetent animals, such as increase in infiltration of immune lymphocytes [35] , upregulation of expression of MHC classes I and II [13, 14] , and accentuation of migration of nonspecific immune cells to necrotic areas in tumor tissues [15] . In immunocompetent mice, in addition to the extensive necrotic foci observed in tumor tissues, more lymphocytes had infiltrated the tumor tissues of the CNHK300-mIFN-g group (Figs. 7A and 7B) compared with the control group (Fig. 7C) + ratios in the CNHK300-mIFN-g, Ad-mIFN-g, and control groups were 1.99 F 0.15, 1.67 F 0.23, and 1.36 F 0.07, respectively. The numbers of LCA + ( P = 0.0001), CD4 + ( P = 0.0005), and CD8 + ( P = 0.0103) cells and the CD4 + /CD8 + ratio ( P = 0.0001) were all increased in tumor tissues of the CNHK300-mIFN-g group compared with the control group. Between the Ad-mIFN-g and the control groups, however, significant differences were observed only in LCA + ( P = 0.0026) and CD4 + /CD8 + ( P = 0.0442). The increase in numbers of LCA + , CD4 + , and CD8 + lymphocytes and the ratio of CD4 + /CD8 + in tumor tissues of the CNHK300-mIFN-g group accounted for the enhancement of immune responses to cancer cells. By pathological examination of liver, lung, kidney, and brain tissues from CNHK300-mIFN-g-treated tumor-bearing mice in Hepa1-6 models, we observed no detectable pathological findings (Fig. 7D) . Hexon immunohistochemistry showed that viral replication occurred only in tumor cells, not in mouse liver cells (Fig. 7E) . These data suggested that mIFN-g discharged from infected tumor cells was not sufficient to cause systemic damage to normal tissues. Our data suggested that although the replication potency of CRAdTs encoding IFN-g was relatively diminished in cancer cells, CRAd-induced intratumor production of IFN-g yielded strong antitumor response without obvious systematic toxicity, which is superior to systematic application of IFN-g product [36] .
In conclusion, the novel immune gene-viral therapeutic systems, which are regulated by the hTERT promoter and contain the IFN-c gene, combine oncolytic virotherapy and immune gene therapy and yield enhanced antitumor efficacy in both immunodeficient and immunocompetent hosts. A theoretical advantage of the systems is that the copies of inserted transgene should increase in number via viral replication within infected cancer cells and the resulting viral progeny should then infect additional cancer cells, and the obtained results strongly support this hypothesis. The transgene expression in normal cells by the tumorselective oncolytic adenoviruses is equal to the traditional gene therapy by replication-deficient adenoviruses and shows little side effect. But in cancer cells, the efficient transgene expression along with the viral selective replication enhanced the antitumor efficacy, which was proved by tumor regression in vivo. CNHK300-mIFN-g and CNHK300-hIFN-g, with improved antitumor activity, thus provide a new and promising strategy for treatment of human cancers, especially large and latestage cancers, and can serve as a prototype for a new modality of antitumor treatment.
MATERIALS AND METHODS
Cells and cell culture. The human cell lines Hep3B, HepG2 (hepatocyte cancer), PANC-1 (pancreatic cancer), A549 (lung cancer), HT-29 (colon cancer), and MRC-5, IMR-90, and BJ (fibroblast cell) were purchased from American Type Culture Collection (Manassas, VA, USA). HEK293 (embryonic kidney cell) was obtained from Microbix Biosystem (Toronto, ON, Canada). SGC-7901 (gastric cancer), SMMC-7721, and mouse hepatocyte cancer cell line Hepa1-6 were obtained from the Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cell lines were cultured in the media recommended by the providers.
Preparation of adenoviruses. Recombination of the replicative adenovirus CNHK300 was previously described [19] , in which the adenoviral E1a gene was driven by a modified hTERT promoter (À212 to +46 bp). A 1046-bp fragment encoding the CMV promoter, mIFN-c cDNA, and SV40 poly(A) was isolated from pCA13-mIFN-g by BglII digestion and inserted into the plasmid for CNHK300 to generate the transfer plasmid for CNHK300-mIFN-g. pCA13-mIFN-g or the transfer plasmid for CNHK300-mIFN-g was cotransfected into HEK293 cells together with the adenovirus packaging plasmid pBGHE3 (Microbix Biosystems, Inc.) to generate the recombinant Ad-mIFN-g and CNHK300-mIFN-g, respectively. The preparations for CNHK300-mIFN-g and CNHK300 showed particle-to-PFU ratios of 25 and 20, respectively. The control adenoviruses CNHK300-hIFN-g and Ad-hIFN-g were constructed by switching mIFN-c to the 501-bp hIFN-c cDNA in the same manner.
Viral replication in vitro. Cell lines were plated in six-well dishes (10 6 cells/well) and cultured until the cancer cells were in log phase and the normal cells appeared to exhibit contact inhibition and were infected with CNHK300-mIFN-g, CNHK300-hIFN-g, CNHK300, ONYX-015 (a gift from A. J. Berk, University of California at Los Angeles, Los Angeles, CA, USA), or wild-type adenovirus 5 (WAd5) at a m.o.i. of 5 pfu/cell. At 48 h after infection, the cells and supernatant were harvested and lysed by three freezing-thawing cycles. The titer data at 48 h were examined in HEK293 cells with the TCID 50 method [37] and normalized to virus production per cell based on the number of infected cells.
Western blot examination of E1a and mIFN-; expression. Cells were seeded in 24-well plates at a density of 5 Â 10 4 cells/well and cultured for 24 h followed by infection with CNHK300-mIFN-g, CNHK300-hIFN-g, CNHK300, or Ad-mIFN-g at a m.o.i. of 1 pfu/cell. Three days after infection, the supernatants were collected for determination of mIFN-g expression, and the cells were harvested and lysed for determination of E1a expression. Western blot assay was performed as described previously [19] , with the rat anti-mouse IFN-g monoclonal antibody (R&D Systems, Inc., Minneapolis, MN, USA) or mouse antiadenoviral E1a monoclonal antibody M73 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
ELISA determination of mIFN-; expression in vitro. Cells were seeded and infected with CNHK300-mIFN-g or Ad-mIFN-g as above. At 48 and 72 h after infection, the cell culture supernatants were centrifuged to remove the dead cell debris and assayed for mIFN-g expression using the Mouse IFN-g ELISA Kit (R&D Systems, Inc.). 3 , and Hep3B tumors reached about 1000 mm 3 in volume, mice were allotted randomly into five groups: CNHK300-mIFN-g, CNHK300, ONYX-015, Ad-mIFN-g, and control groups, n = 16 mice/group for SMMC-7721 models, with 6/16 mice per group prepared to sacrifice for detecting mIFN-g expression; n = 10 mice/group for Hep3B models; and n = 5 mice/group for Hepa1-6 models. Mice underwent five intratumoral injections, once every other day, with a total dosage of 10 9 pfu per mouse in the virus-treated groups and with 100
Al viral preservation solution (10 mM Tris-HCl, pH 8.0, 2 mM MgCl 2 , 4% sucrose) per mouse per injection in the control group. Tumor sizes were measured regularly. Tumor volume was estimated as a Â b 2 Â 0.5, where a and b were the maximal and minimal diameters, respectively. At days 3 and 7 after treatment in SMMC-7721 models, 3 mice per group per time point were sacrificed to collect serum by retroorbital puncture. The mIFNg expression in mouse serum was measured using the Mouse IFN-g ELISA Kit.
For Hepa1-6 and Hep3B models, mice were killed 1 and 2 months later, respectively, by cervical dislocation. Tumors and organs were removed and fixed in 10% neutral formaldehyde for 6 h and paraffinembedded, and 5-Am-thick consecutive sections were cut for H&E staining and immunohistochemistry. On sections of Hep3B models, the expression of adenoviral capsid protein hexon was located using the mouse antiadenoviral hexon antibody (Biodesign International, Saco, MA, USA). Quantitative analysis of blood vessels in tumor tissues was also performed by CD31 immunohistochemistry using the rat anti-mouse CD31 monoclonal antibody (BD Biosciences Pharmingen, San Diego, CA, USA). On sections of Hepa1-6 models, the infiltrating lymphocytes were localized immunohistochemically with leukocyte common antigen (LCA), CD4, and CD8 antibodies (Zymed Laboratories, South San Francisco, CA, USA) in tumor tissues, and hexon expression was determined in organ tissues. Cells positive for hexon, LCA, CD4, and CD8 and the MVDs were counted within four high-power fields under a light microscope.
Statistical analysis. All in vitro experiments were performed three times, and the data are presented as the means F standard deviation and assessed by StudentTs t test. The data of in vivo experiments were assessed by analysis of variance (ANOVA). The synergistic antitumor efficacy between the adenoviral oncolysis and the mIFN-g antitumor effect was analyzed by two-way ANOVA with a repeated measurement. Findings of P b 0.05 were considered significant.
